Expanded access to experimental drugs: activists seek more open programs.
Grinberg
L
L
Foundation for AIDS and Immune Research, Los Angeles, CA.
D019380:Anti-HIV Agents / Q000600:supply & distribution* / Q000627:therapeutic use; D002219:Carbamates; D002986:Clinical Trials as Topic; D015224:Dideoxynucleosides / Q000600:supply & distribution* / Q000627:therapeutic use; D004345:Drug Industry; D005663:Furans; D017320:HIV Protease Inhibitors / Q000600:supply & distribution* / Q000627:therapeutic use; D006297:Health Services Accessibility; D006801:Humans; D018894:Reverse Transcriptase Inhibitors / Q000600:supply & distribution* / Q000627:therapeutic use; D013449:Sulfonamides / Q000600:supply & distribution* / Q000627:therapeutic use; D000099227:Abacavir
D019380:Anti-HIV Agents; D002219:Carbamates; D015224:Dideoxynucleosides; D005663:Furans; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D013449:Sulfonamides; D000099227:Abacavir; C095108:amprenavir